Bank of England chief economist Pill said fine-tuning interest rates is problematic amid energy-price uncertainty.

China’s National Medical Products Administration approved Genzyme Corporation’s Class 1 innovative drug rilzabrutinib tablets (trade name Sailizhi) for adults with persistent or chronic primary immune thrombocytopenia (ITP) who had inadequate response or intolerance to corticosteroids, IVIG or other prior therapies. The approval establishes a new treatment option for this patient population in China.

Meta发布Muse Spark 1.3，现已开放的xhigh版本跻身前沿模型梯队；CrowdStrike与OpenAI把Codex代理防护推进到运行时，HiddenLayer再获1亿美元融资；科学与产业端，Physical Superintelligence携5800万美元出场，C3 AI则首次转为自由现金流为正。